Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 920618, 12 pages
http://dx.doi.org/10.1155/2015/920618
Review Article

The Association between Type 2 Diabetes Mellitus and Women Cancer: The Epidemiological Evidences and Putative Mechanisms

1Department of Internal Medicine, Chungnam National University School of Medicine, 282 Munhwa-ro, Jung-gu, Daejeon 301-721, Republic of Korea
2Department of Obstetrics, Gynecology and Reproductive Biology, Michigan State University, College of Human Medicine, 333 Bostwick Avenue NE, Grand Rapids, MI 49503, USA

Received 24 June 2014; Revised 12 September 2014; Accepted 8 October 2014

Academic Editor: Viroj Boonyaratanakornkit

Copyright © 2015 Kyong Hye Joung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Rathmann, G. Giani, S. H. Wild et al., “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 10, pp. 2568–2569, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Zhang, X. Zhang, J. Brown et al., “Global healthcare expenditure on diabetes for 2010 and 2030,” Diabetes Research and Clinical Practice, vol. 87, no. 3, pp. 293–301, 2030. View at Publisher · View at Google Scholar
  3. P. T. Campbell, E. J. Jacobs, C. C. Newton, S. M. Gapstur, and A. V. Patel, “Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults,” Diabetes Care, vol. 35, no. 9, pp. 1835–1844, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. S. R. Seshasai, S. Kaptoge, A. Thompson et al., “Diabetes mellitus, fasting glucose, and risk of cause-specific death,” The New England Journal of Medicine, vol. 364, no. 9, pp. 829–841, 2011. View at Publisher · View at Google Scholar
  5. S. S. Coughlin, E. E. Calle, L. R. Teras, J. Petrelli, and M. J. Thun, “Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults,” American Journal of Epidemiology, vol. 159, no. 12, pp. 1160–1167, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. S. D. Nath, S. L. Habib, H. E. Abboud et al., “Fasting serum glucose level and cancer risk in Korean men and women,” Journal of the American Medical Association, vol. 293, no. 18, pp. 2210–2211, 2005. View at Google Scholar · View at Scopus
  7. G. Chodick, A. D. Heymann, L. Rosenmann et al., “Diabetes and risk of incident cancer: a large population-based cohort study in Israel,” Cancer Causes and Control, vol. 21, no. 6, pp. 879–887, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. E. K. K. Lam, G. D. Batty, R. R. Huxley et al., “Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region,” Annals of Oncology, vol. 22, no. 3, pp. 730–738, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Handelsman, D. Leroith, Z. T. Bloomgarden et al., “Diabetes and cancer—an AACE/ACE consensus statement,” Endocrine Practice, vol. 19, no. 4, pp. 675–693, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Czyzyk and Z. Szczepanik, “Diabetes mellitus and cancer,” European Journal of Internal Medicine, vol. 11, no. 5, pp. 245–252, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. S. C. Larsson, C. S. Mantzoros, and A. Wolk, “Diabetes mellitus and risk of breast cancer: a meta-analysis,” International Journal of Cancer, vol. 121, no. 4, pp. 856–862, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. S. C. Larsson, N. Orsini, and A. Wolk, “Diabetes mellitus and risk of colorectal cancer: a meta-analysis,” Journal of the National Cancer Institute, vol. 97, no. 22, pp. 1679–1687, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Friberg, N. Orsini, C. S. Mantzoros, and A. Wolk, “Diabetes mellitus and risk of endometrial cancer: a meta-analysis,” Diabetologia, vol. 50, no. 7, pp. 1365–1374, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. E. M. Ko, P. Walter, L. Clark et al., “The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance,” Gynecologic Oncology, vol. 133, no. 1, pp. 28–32, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. H.-F. Chen, M.-D. Liu, P. Chen et al., “Risks of breast and endometrial cancer in women with diabetes: a population-based cohort study,” PLoS ONE, vol. 8, no. 6, Article ID e67420, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Huxley, A. Ansary-Moghaddam, A. Berrington de González, F. Barzi, and M. Woodward, “Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies,” British Journal of Cancer, vol. 92, no. 11, pp. 2076–2083, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. H. B. El-Serag, H. Hampel, and F. Javadi, “The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence,” Clinical Gastroenterology and Hepatology, vol. 4, no. 3, pp. 369–380, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Fang, B. Yao, Y. Yan et al., “Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis of observational studies,” Diabetes Technology and Therapeutics, vol. 15, no. 11, pp. 914–922, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. B. B. Barone, H.-C. Yeh, C. F. Snyder et al., “Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis,” The Journal of the American Medical Association, vol. 300, no. 23, pp. 2754–2764, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Clarke, M. Shipley, S. Lewington et al., “Underestimation of risk associations due to regression dilution in long- term follow-up of prospective studies,” The American Journal of Epidemiology, vol. 150, no. 4, pp. 341–353, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. S. L. Habib and M. Rojna, “Diabetes and risk of cancer,” ISRN Oncology, vol. 2013, Article ID 583786, 16 pages, 2013. View at Publisher · View at Google Scholar
  22. F. Ikeda, Y. Doi, K. Yonemoto et al., “Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study,” Gastroenterology, vol. 136, no. 4, pp. 1234–1241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. T. N. Le, J. E. Nestler, J. F. Strauss, and E. P. Wickham, “Sex hormone-binding globulin and type 2 diabetes mellitus,” Trends in Endocrinology & Metabolism, vol. 23, no. 1, pp. 32–40, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. S. K. Pal and A. Hurria, “Impact of age, sex, and comorbidity on cancer therapy and disease progression,” Journal of Clinical Oncology, vol. 28, no. 26, pp. 4086–4093, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. J. H. Koo and R. W. L. Leong, “Sex differences in epidemiological, clinical and pathological characteristics of colorectal cancer,” Journal of Gastroenterology and Hepatology, vol. 25, no. 1, pp. 33–42, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Pollak, “Insulin and insulin-like growth factor signalling in neoplasia,” Nature Reviews Cancer, vol. 8, no. 12, pp. 915–928, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. J. A. Cooper, D. F. Bowen-Pope, E. Raines, R. Ross, and T. Hunter, “Similar effects of platelet-derived growth factor and epidermal growth factor on the phosphorylation of tyrosine in cellular proteins,” Cell, vol. 31, no. 1, pp. 263–273, 1982. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Chegini, M. J. Rossi, and B. J. Masterson, “Platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and EGF and PDGF β-receptors in human endometrial tissue: localization and in vitro action,” Endocrinology, vol. 130, no. 4, pp. 2373–2385, 1992. View at Publisher · View at Google Scholar · View at Scopus
  29. Z. Laron, “IGF-1 and insulin as growth hormones,” Novartis Foundation Symposium, vol. 262, pp. 56–83, 265–268, 2004. View at Google Scholar
  30. V. Pezzino, A. Costantino, P. Russo, D. Gullo, and V. Papa, “Insulin receptor content in tissues of normal and diabetic rats measured by radioimunoassay,” Journal of Endocrinological Investigation, vol. 19, no. 9, pp. 593–597, 1996. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Hernández-Sánchez, A. Mansilla, F. De Pablo, and R. Zardoya, “Evolution of the insulin receptor family and receptor isoform expression in vertebrates,” Molecular Biology and Evolution, vol. 25, no. 6, pp. 1043–1053, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. P. de Meyts, “Insulin and its receptor: structure, function and evolution,” BioEssays, vol. 26, no. 12, pp. 1351–1362, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. E. S. Schernhammer, J. M. Holly, D. J. Hunter, M. N. Pollak, and S. E. Hankinson, “Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II,” Endocrine-Related Cancer, vol. 13, no. 2, pp. 583–592, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Belfiore, F. Frasca, G. Pandini, L. Sciacca, and R. Vigneri, “Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease,” Endocrine Reviews, vol. 30, no. 6, pp. 586–623, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Benyoucef, K. H. Surinya, D. Hadaschik, and K. Siddle, “Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation,” Biochemical Journal, vol. 403, no. 3, pp. 603–613, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. D. LeRoith, “Insulin-like growth factor I receptor signaling—overlapping or redundant pathways?” Endocrinology, vol. 141, no. 4, pp. 1287–1288, 2000. View at Google Scholar
  37. P. J. Jenkins, “Cancers associated with acromegaly,” Neuroendocrinology, vol. 83, no. 3-4, pp. 218–223, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. E. E. Calle, C. Rodriguez, K. Walker-Thurmond, and M. J. Thun, “Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults,” The New England Journal of Medicine, vol. 348, no. 17, pp. 1625–1638, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. D. L. Roberts, C. Dive, and A. G. Renehan, “Biological mechanisms linking obesity and cancer risk: new perspectives,” Annual Review of Medicine, vol. 61, pp. 301–316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. D. H. Cohen and D. LeRoith, “Obesity, type 2 diabetes, and cancer: the insulin and IGF connection,” Endocrine-Related Cancer, vol. 19, no. 5, pp. F27–F45, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Gu, C. Wang, Y. Zheng et al., “Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: a cohort study in Shanghai,” PLoS ONE, vol. 8, no. 1, Article ID e53411, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Ma, H. Li, E. Giovannucci et al., “Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis,” The Lancet Oncology, vol. 9, no. 11, pp. 1039–1047, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Ma, E. Giovannucci, M. Pollak et al., “A prospective study of plasma C-peptide and colorectal cancer risk in men,” Journal of the National Cancer Institute, vol. 96, no. 7, pp. 546–553, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Dankner, M. H. Shanik, L. Keinan-Boker, C. Cohen, and A. Chetrit, “Effect of elevated basal insulin on cancer incidence and mortality in cancer incident patients: the Israel GOH 29-year follow-up study,” Diabetes Care, vol. 35, no. 7, pp. 1538–1543, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Lippman, G. Bolan, and K. Huff, “The effects of estrogens and antiestrogens on hormone responsive human breast cancer in long term tissue culture,” Cancer Research, vol. 36, no. 12, pp. 4595–4601, 1976. View at Google Scholar · View at Scopus
  46. C. K. Osborne, G. Bolan, M. E. Monaco, and M. E. Lippman, “Hormone responsive human breast cancer in long term tissue culture: effect of insulin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 73, no. 12, pp. 4536–4540, 1976. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Zhang, D. H. Fagan, X. Zeng, K. T. Freeman, D. Sachdev, and D. Yee, “Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation,” Oncogene, vol. 29, no. 17, pp. 2517–2527, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. J. C. Heuson and N. Legros, “Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction.,” Cancer Research, vol. 32, no. 2, pp. 226–232, 1972. View at Google Scholar · View at Scopus
  49. S. M. Firth and R. C. Baxter, “Cellular actions of the insulin-like growth factor binding proteins,” Endocrine Reviews, vol. 23, no. 6, pp. 824–854, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. V. A. Ezzat, E. R. Duncan, S. B. Wheatcroft, and M. T. Kearney, “The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease,” Diabetes, Obesity and Metabolism, vol. 10, no. 3, pp. 198–211, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Söderberg, B. Ahrén, M. Eliasson, B. Dinesen, K. Brismar, and T. Olsson, “Circulating IGF binding protein-1 is inversely associated with leptin in non-obese men and obese postmenopausal women,” European Journal of Endocrinology, vol. 144, no. 3, pp. 283–290, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. A. López-Bermejo, J. Khosravi, J. M. Fernández-Real et al., “Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1/MAC25),” Diabetes, vol. 55, no. 8, pp. 2333–2339, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. D. P. Rose and L. Vona-Davis, “The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression,” Endocrine-Related Cancer, vol. 19, no. 6, pp. R225–R241, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. N. Mu, Y. Zhu, Y. Wang, H. Zhang, and F. Xue, “Insulin resistance: a significant risk factor of endometrial cancer,” Gynecologic Oncology, vol. 125, no. 3, pp. 751–757, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. M. C. Beauchamp, A. Yasmeen, A. Knafo, and W. H. Gotlieb, “Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer,” Journal of Oncology, vol. 2010, Article ID 257058, 11 pages, 2010. View at Publisher · View at Google Scholar
  56. M. Pollak, “The insulin and insulin-like growth factor receptor family in neoplasia: an update,” Nature Reviews Cancer, vol. 12, no. 3, pp. 159–169, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. P. K. Siiteri, “Steroid hormones and endometrial cancer,” Cancer Research, vol. 38, no. 11, part 2, pp. 4360–4366, 1978. View at Google Scholar · View at Scopus
  58. T. J. A. Key and M. C. Pike, “The dose-effect relationship between “unopposed” oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk,” British Journal of Cancer, vol. 57, no. 2, pp. 205–212, 1988. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Lukanova and R. Kaaks, “Endogenous hormones and ovarian cancer: epidemiology and current hypotheses,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 1, pp. 98–107, 2005. View at Google Scholar · View at Scopus
  60. A. Ferenczy, G. Bertrand, and M. M. Gelfand, “Proliferation kinetics of human endometrium during the normal menstrual cycle,” American Journal of Obstetrics & Gynecology, vol. 133, no. 8, pp. 859–867, 1979. View at Google Scholar · View at Scopus
  61. C. L. Wilson, A. H. Sims, A. Howell, C. J. Miller, and R. B. Clarke, “Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue,” Endocrine-Related Cancer, vol. 13, no. 2, pp. 617–628, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Stingl, “Estrogen and progesterone in normal mammary gland development and in cancer,” Hormones and Cancer, vol. 2, no. 2, pp. 85–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. R. F. Spengler, E. A. Clarke, C. A. Woolever, A. M. Newman, and R. W. Osborn, “Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases,” American Journal of Epidemiology, vol. 114, no. 4, pp. 497–506, 1981. View at Google Scholar · View at Scopus
  64. E. J. Crosbie, M. Zwahlen, H. C. Kitchener, M. Egger, and A. G. Renehan, “Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 12, pp. 3119–3130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. K. K. Steinberg, S. B. Thacker, S. J. Smith et al., “A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer,” The Journal of the American Medical Association, vol. 265, no. 15, pp. 1985–1990, 1991. View at Publisher · View at Google Scholar · View at Scopus
  66. C. Magnusson, I. Persson, and H.-O. Adami, “More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin,” Journal of the National Cancer Institute, vol. 92, no. 14, pp. 1183–1184, 2000. View at Publisher · View at Google Scholar · View at Scopus
  67. P. G. Toniolo, M. Levitz, A. Zeleniuch-Jacquotte et al., “A prospective study of endogenous estrogens and breast cancer in postmenopausal women,” Journal of the National Cancer Institute, vol. 87, no. 3, pp. 190–197, 1995. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Akhmedkhanov, A. Zeleniuch-Jacquotte, and P. Toniolo, “Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives,” Annals of the New York Academy of Sciences, vol. 943, pp. 296–315, 2001. View at Google Scholar · View at Scopus
  69. C. M. Friedenreich, “Review of anthropometric factors and breast cancer risk,” European Journal of Cancer Prevention, vol. 10, no. 1, pp. 15–32, 2001. View at Publisher · View at Google Scholar · View at Scopus
  70. S. C. Sommers, A. T. Hertig, and H. Bengloff, “Genesis of endometrial carcinoma; cases 19 to 35 years old,” Cancer, vol. 2, no. 6, pp. 957–963, 1949. View at Publisher · View at Google Scholar · View at Scopus
  71. E. Ron, B. Lunenfeld, J. Menczer et al., “Cancer incidence in a cohort of infertile women,” American Journal of Epidemiology, vol. 125, no. 5, pp. 780–790, 1987. View at Google Scholar · View at Scopus
  72. S. Wild, T. Pierpoint, H. Jacobs, and P. McKeigue, “Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study,” Human Fertility, vol. 3, no. 2, pp. 101–105, 2000. View at Publisher · View at Google Scholar · View at Scopus
  73. C. B. Coulam, J. F. Annegers, and J. S. Kranz, “Chronic anovulation syndrome and associated neoplasia,” Obstetrics and Gynecology, vol. 61, no. 4, pp. 403–407, 1983. View at Google Scholar · View at Scopus
  74. A. Daniilidis and K. Dinas, “Long term health consequences of polycystic ovarian syndrome: a review analysis,” Hippokratia, vol. 13, no. 2, pp. 90–92, 2009. View at Google Scholar · View at Scopus
  75. N. Potischman, R. N. Hoover, L. A. Brinton et al., “Case-control study of endogenous steroid hormones and endometrial cancer,” Journal of the National Cancer Institute, vol. 88, no. 16, pp. 1127–1135, 1996. View at Publisher · View at Google Scholar · View at Scopus
  76. B. Pettersson, R. Bergstrom, and E. D. B. Johansson, “Serum estrogens and androgens in women with endometrial carcinoma,” Gynecologic Oncology, vol. 25, no. 2, pp. 223–233, 1986. View at Publisher · View at Google Scholar · View at Scopus
  77. H. C. J. Nyholm, A. L. Nielsen, J. Lyndrup, A. Dreisler, C. Hagen, and E. Haug, “Plasma oestrogens in postmenopausal women with endometrial cancer,” British Journal of Obstetrics and Gynaecology, vol. 100, no. 12, pp. 1115–1119, 1993. View at Publisher · View at Google Scholar · View at Scopus
  78. J. A. Nisker, G. L. Hammond, B. J. Davidson et al., “Serum sex hormone-binding globulin capacity and the percentage of free estradiol in postmenopausal women with and without endometrial carcinoma. A new biochemical basis for the association between obesity and endometrial carcinoma,” American Journal of Obstetrics and Gynecology, vol. 138, no. 6, pp. 637–642, 1980. View at Google Scholar · View at Scopus
  79. J. M. Schildkraut, P. J. Schwingl, E. Bastos, A. Evanoff, C. Hughes, and J. P. Curtin, “Epithelial ovarian cancer risk among women with polycystic ovary syndrome,” Obstetrics & Gynecology, vol. 88, no. 4, part 1, pp. 554–559, 1996. View at Publisher · View at Google Scholar · View at Scopus
  80. E. G. Silva, C. Tornos, H. A. Fritsche Jr. et al., “The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model,” Modern Pathology, vol. 10, no. 9, pp. 879–883, 1997. View at Google Scholar · View at Scopus
  81. I. Wiegratz, C. Jung-Hoffmann, and H. Kuhl, “Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins,” Contraception, vol. 51, no. 6, pp. 341–346, 1995. View at Publisher · View at Google Scholar · View at Scopus
  82. N. Fortunati, M. G. Catalano, G. Boccuzzi, and R. Frairia, “Sex Hormone-Binding Globulin (SHBG), estradiol and breast cancer,” Molecular and Cellular Endocrinology, vol. 316, no. 1, pp. 86–92, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. G. N. Armaiz-Pena, L. S. Mangala, W. A. Spannuth et al., “Estrous cycle modulates ovarian carcinoma growth,” Clinical Cancer Research, vol. 15, no. 9, pp. 2971–2978, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. C.-H. Chien, F.-F. Wang, and T. C. Hamilton, “Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells,” Molecular and Cellular Endocrinology, vol. 99, no. 1, pp. 11–19, 1994. View at Publisher · View at Google Scholar · View at Scopus
  85. A. V. Lee, J. G. Jackson, J. L. Gooch et al., “Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo,” Molecular Endocrinology, vol. 13, no. 5, pp. 787–796, 1999. View at Publisher · View at Google Scholar · View at Scopus
  86. L. C. Giudice, G. Lamson, R. G. Rosenfeld, and J. C. Irwin, “Insulin-like growth factor-II (IGF-II) and IGF binding proteins in human endometrium,” Annals of the New York Academy of Sciences, vol. 626, pp. 295–307, 1991. View at Publisher · View at Google Scholar · View at Scopus
  87. L. J. Murphy and A. Ghahary, “Uterine insulin-like growth factor-1: regulation of expression and its role in estrogen-induced uterine proliferation,” Endocrine Reviews, vol. 11, no. 3, pp. 443–453, 1990. View at Publisher · View at Google Scholar · View at Scopus
  88. V. Bartella, P. de Marco, R. Malaguarnera, A. Belfiore, and M. Maggiolini, “New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer,” Cellular Signalling, vol. 24, no. 8, pp. 1515–1521, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. D. H. Fagan, R. R. Uselman, D. Sachdev, and D. Yee, “Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment,” Cancer Research, vol. 72, no. 13, pp. 3372–3380, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. T. Winder, G. Giamas, P. M. Wilson et al., “Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen,” Pharmacogenomics Journal, vol. 14, no. 1, pp. 28–34, 2014. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Periyasamy-Thandavan, S. Takhar, A. Singer et al., “Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim,” Breast Cancer Research, vol. 14, no. 2, p. R52, 2012. View at Publisher · View at Google Scholar · View at Scopus
  92. V. Syed, G. Ulinski, S. C. Mok, and S.-M. Ho, “Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells,” Journal of the National Cancer Institute, vol. 94, no. 8, pp. 617–629, 2002. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Qiu, W. Bao, J. Wang et al., “FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer,” BMC Cancer, vol. 14, no. 1, article 78, 2014. View at Publisher · View at Google Scholar · View at Scopus
  94. L. E. Underwood, J.-P. Thissen, S. Lemozy, J.-M. Ketelslegers, and D. R. Clemmons, “Hormonal and nutritional regulation of IGF-I and its binding proteins,” Hormone Research, vol. 42, no. 4-5, pp. 145–151, 1994. View at Publisher · View at Google Scholar · View at Scopus
  95. J.-P. Thissen, J.-M. Ketelslegers, and L. E. Underwood, “Nutritional regulation of the insulin-like growth factors,” Endocrine Reviews, vol. 15, no. 1, pp. 80–101, 1994. View at Publisher · View at Google Scholar · View at Scopus
  96. R. Pasquali, V. Vicennati, D. Bertazzo et al., “Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status,” Metabolism: Clinical and Experimental, vol. 46, no. 1, pp. 5–9, 1997. View at Publisher · View at Google Scholar · View at Scopus
  97. D. P. Rose, D. Komninou, and G. D. Stephenson, “Obesity, adipocytokines, and insulin resistance in breast cancer,” Obesity Reviews, vol. 5, no. 3, pp. 153–165, 2004. View at Publisher · View at Google Scholar · View at Scopus
  98. D. Pardoll, “Does the immune system see tumors as foreign or self?” Annual Review of Immunology, vol. 21, pp. 807–839, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Philip, D. A. Rowley, and H. Schreiber, “Inflammation as a tumor promoter in cancer induction,” Seminars in Cancer Biology, vol. 14, no. 6, pp. 433–439, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. J.-L. Luo, S. Maeda, L.-C. Hsu, H. Yagita, and M. Karin, “Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression,” Cancer Cell, vol. 6, no. 3, pp. 297–305, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. M. Karin and F. R. Greten, “NF-κB: linking inflammation and immunity to cancer development and progression,” Nature Reviews Immunology, vol. 5, no. 10, pp. 749–759, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. K. Esposito, P. Chiodini, A. Colao, A. Lenzi, and D. Giugliano, “Metabolic syndrome and risk of cancer: a systematic review and meta-analysis,” Diabetes Care, vol. 35, no. 11, pp. 2402–2411, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. P. Pothiwala, S. K. Jain, and S. Yaturu, “Metabolic syndrome and cancer,” Metabolic Syndrome and Related Disorders, vol. 7, no. 4, pp. 279–287, 2009. View at Publisher · View at Google Scholar · View at Scopus
  104. K. Garber, “Aspirin for cancer chemoprevention: still a headache?” Journal of the National Cancer Institute, vol. 96, no. 4, pp. 252–253, 2004. View at Publisher · View at Google Scholar · View at Scopus
  105. R. B. Ness and C. Cottreau, “Possible role of ovarian epithelial inflammation in ovarian cancer,” Journal of the National Cancer Institute, vol. 91, no. 17, pp. 1459–1467, 1999. View at Publisher · View at Google Scholar · View at Scopus
  106. D. K. Biswas, Q. Shi, S. Baily et al., “NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 27, pp. 10137–10142, 2004. View at Google Scholar
  107. L. A. deGraffenried, B. Chandrasekar, W. E. Friedrichs et al., “NF-κB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen,” Annals of Oncology, vol. 15, no. 6, pp. 885–890, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. A. E. Wallace, D. A. Gibson, P. T. K. Saunders, and H. N. Jabbour, “Inflammatory events in endometrial adenocarcinoma,” Journal of Endocrinology, vol. 206, no. 2, pp. 141–157, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. A. B. Alvero, “Recent insights into the role of NF-κB in ovarian carcinogenesis,” Genome Medicine, vol. 2, no. 8, article 56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. C. de Luca and J. M. Olefsky, “Inflammation and insulin resistance,” FEBS Letters, vol. 582, no. 1, pp. 97–105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. M. Y. Donath and S. E. Shoelson, “Type 2 diabetes as an inflammatory disease,” Nature Reviews Immunology, vol. 11, no. 2, pp. 98–107, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. K. H. Seo, H.-S. Lee, B. Jung et al., “Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-κB activation,” Cancer Research, vol. 64, no. 18, pp. 6482–6488, 2004. View at Publisher · View at Google Scholar · View at Scopus
  113. F. Modugno, R. B. Ness, C. Chen, and N. S. Weiss, “Inflammation and endometrial cancer: a hypothesis,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 12, pp. 2840–2847, 2005. View at Publisher · View at Google Scholar · View at Scopus
  114. C. la Vecchia, S. H. Giordano, G. N. Hortobagyi, and B. Chabner, “Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle,” Oncologist, vol. 16, no. 6, pp. 726–729, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. K. B. Michels, C. G. Solomon, F. B. Hu et al., “Type 2 diabetes and subsequent incidence of breast cancer in the nurses' health study,” Diabetes Care, vol. 26, no. 6, pp. 1752–1758, 2003. View at Publisher · View at Google Scholar · View at Scopus
  116. L. L. Lipscombe, P. J. Goodwin, B. Zinman, J. R. McLaughlin, and J. E. Hux, “The impact of diabetes on survival following breast cancer,” Breast Cancer Research and Treatment, vol. 109, no. 2, pp. 389–395, 2008. View at Publisher · View at Google Scholar · View at Scopus
  117. C. J. Currie, C. D. Poole, S. Jenkins-Jones, E. A. M. Gale, J. A. Johnson, and C. L. Morgan, “Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival,” Diabetes Care, vol. 35, no. 2, pp. 299–304, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. J.-Y. Chen, W.-K. Chiou, W.-Y. Chou, and J.-D. Lin, “The impact of type 2 diabetes mellitus on mortality in hospitalized female cancer patients in Taiwan,” Asia-Pacific Journal of Clinical Oncology, 2013. View at Publisher · View at Google Scholar · View at Scopus
  119. S. Liao, J. Li, W. Wei et al., “Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature,” Asian Pacific Journal of Cancer Prevention, vol. 12, no. 4, pp. 1061–1065, 2011. View at Google Scholar · View at Scopus
  120. L. Sciacca, A. Costantino, G. Pandini et al., “Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism,” Oncogene, vol. 18, no. 15, pp. 2471–2479, 1999. View at Publisher · View at Google Scholar · View at Scopus
  121. R. Novosyadlyy, D. E. Lann, A. Vijayakumar et al., “Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes,” Cancer Research, vol. 70, no. 2, pp. 741–751, 2010. View at Publisher · View at Google Scholar · View at Scopus
  122. H. Nyholm, H. Djursing, C. Hagen, T. Agner, P. Bennett, and B. Svenstrup, “Androgens and estrogens in postmenopausal insulin-treated diabetic women,” The Journal of Clinical Endocrinology and Metabolism, vol. 69, no. 5, pp. 946–949, 1989. View at Publisher · View at Google Scholar · View at Scopus
  123. L. Vona-Davis and D. P. Rose, “Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy,” Current Diabetes Reviews, vol. 8, no. 2, pp. 116–130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  124. B. S. Katzenellenbogen and M. J. Norman, “Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: Interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen,” Endocrinology, vol. 126, no. 2, pp. 891–898, 1990. View at Publisher · View at Google Scholar · View at Scopus
  125. M. L. Panno, M. Salerno, V. Pezzi et al., “Effect of oestradiol and insulin on the proliferative pattern and on oestrogen and progesterone receptor contents in MCF-7 cells,” Journal of Cancer Research and Clinical Oncology, vol. 122, no. 12, pp. 745–749, 1996. View at Publisher · View at Google Scholar · View at Scopus
  126. L. Mauro, M. Salerno, M. L. Panno et al., “Estradiol increases IRS-1 gene expression and insulin signaling in breast cancer cells,” Biochemical and Biophysical Research Communications, vol. 288, no. 3, pp. 685–689, 2001. View at Publisher · View at Google Scholar · View at Scopus
  127. A. Purohit, S. P. Newman, and M. J. Reed, “The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer,” Breast Cancer Research, vol. 4, no. 2, pp. 65–69, 2002. View at Publisher · View at Google Scholar · View at Scopus
  128. A. Di Cristofano and L. H. Ellenson, “Endometrial carcinoma,” Annual Review of Pathology, vol. 2, pp. 57–85, 2007. View at Publisher · View at Google Scholar · View at Scopus
  129. S. S. Jick, A. M. Walker, and H. Jick, “Estrogens, progesterone, and endometrial cancer,” Epidemiology, vol. 4, no. 1, pp. 20–24, 1993. View at Publisher · View at Google Scholar · View at Scopus
  130. K. E. Anderson, E. Anderson, P. J. Mink et al., “Diabetes and endometrial cancer in the Iowa Women's Health Study,” Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 6, pp. 611–616, 2001. View at Google Scholar · View at Scopus
  131. Y. Zhang, Z. Liu, X. Yu et al., “The association between metabolic abnormality and endometrial cancer: a large case-control study in China,” Gynecologic Oncology, vol. 117, no. 1, pp. 41–46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  132. E. Friberg, C. S. Mantzoros, and A. Wolk, “Diabetes and risk of endometrial cancer: a population-based prospective cohort study,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 2, pp. 276–280, 2007. View at Publisher · View at Google Scholar · View at Scopus
  133. H. Vainio, R. Kaaks, and F. Bianchini, “Weight control and physical activity in cancer prevention: international evaluation of the evidence,” European Journal of Cancer Prevention, vol. 11, supplement 2, pp. S94–S100, 2002. View at Google Scholar · View at Scopus
  134. L. J. Schouten, R. A. Goldbohm, and P. A. van den Brandt, “Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study,” Journal of the National Cancer Institute, vol. 96, no. 21, pp. 1635–1638, 2004. View at Publisher · View at Google Scholar · View at Scopus
  135. S. C. Modesitt and J. R. Van Nagell Jr., “The impact of obesity on the incidence and treatment of gynecologic cancers: a review,” Obstetrical and Gynecological Survey, vol. 60, no. 10, pp. 683–692, 2005. View at Publisher · View at Google Scholar · View at Scopus
  136. I. Bruchim, R. Sarfstein, and H. Werner, “The IGF hormonal network in endometrial cancer: functions, regulation, and targeting approaches,” Frontiers in Endocrinology, vol. 5, p. 76, 2014. View at Publisher · View at Google Scholar
  137. T. Wang, T. E. Rohan, M. J. Gunter et al., “A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers,” Cancer Epidemiology Biomarkers and Prevention, vol. 20, no. 5, pp. 971–977, 2011. View at Publisher · View at Google Scholar · View at Scopus
  138. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  139. B. T. Hennessy, R. L. Coleman, and M. Markman, “Ovarian cancer,” The Lancet, vol. 374, no. 9698, pp. 1371–1382, 2009. View at Publisher · View at Google Scholar · View at Scopus
  140. V. Beral, R. Doll, C. Hermon et al., “Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls,” The Lancet, vol. 371, no. 9609, pp. 303–314, 2008. View at Publisher · View at Google Scholar · View at Scopus
  141. L. Poretsky and M. F. Kalin, “The gonadotropic function of insulin.,” Endocrine Reviews, vol. 8, no. 2, pp. 132–141, 1987. View at Publisher · View at Google Scholar · View at Scopus
  142. R. J. Chang, R. M. Nakamura, H. L. Judd, and S. A. Kaplan, “Insulin resistance in nonobese patients with polycystic ovarian disease,” Journal of Clinical Endocrinology and Metabolism, vol. 57, no. 2, pp. 356–359, 1983. View at Publisher · View at Google Scholar · View at Scopus
  143. A. I. Adler, N. S. Weiss, M. L. Kamb, and J. L. Lyon, “Is diabetes mellitus a risk factor for ovarian cancer? A case-control study in Utah and Washington (United States),” Cancer Causes and Control, vol. 7, no. 4, pp. 475–478, 1996. View at Publisher · View at Google Scholar · View at Scopus
  144. J.-Y. Lee, I. Jeon, J. W. Kim, Y.-S. Song, J.-M. Yoon, and S. M. Park, “Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies,” International Journal of Gynecological Cancer, vol. 23, no. 3, pp. 402–412, 2013. View at Publisher · View at Google Scholar · View at Scopus
  145. L. Wideroff, G. Gridley, L. Mellemkjaer et al., “Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in denmark,” Journal of the National Cancer Institute, vol. 89, no. 18, pp. 1360–1365, 1997. View at Publisher · View at Google Scholar · View at Scopus
  146. S.-F. Lo, S.-N. Chang, C.-H. Muo et al., “Modest increase in risk of specific types of cancer types in type 2 diabetes mellitus patients,” International Journal of Cancer, vol. 132, no. 1, pp. 182–188, 2013. View at Publisher · View at Google Scholar · View at Scopus
  147. H. A. Risch, “Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone,” Journal of the National Cancer Institute, vol. 90, no. 23, pp. 1774–1786, 1998. View at Publisher · View at Google Scholar · View at Scopus
  148. M.-R. Shen, A.-C. Lin, Y.-M. Hsu et al., “Insulin-like growth factor 1 stimulates KCl cotransport, which is necessary for invasion and proliferation of cervical cancer and ovarian cancer cells,” The Journal of Biological Chemistry, vol. 279, no. 38, pp. 40017–40025, 2004. View at Publisher · View at Google Scholar · View at Scopus
  149. Y. Tanaka, H. Kobayashi, M. Suzuki, Y. Hirashima, N. Kanayama, and T. Terao, “Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis,” International Journal of Cancer, vol. 109, no. 3, pp. 336–347, 2004. View at Publisher · View at Google Scholar · View at Scopus
  150. E. J. Lee, C. Mircean, I. Shmulevich et al., “Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion,” Molecular Cancer, vol. 4, article 7, 2005. View at Publisher · View at Google Scholar · View at Scopus
  151. T. V. Clendenen, E. Lundin, A. Zeleniuch-Jacquotte et al., “Circulating inflammation markers and risk of epithelial ovarian cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 20, no. 5, pp. 799–810, 2011. View at Publisher · View at Google Scholar · View at Scopus
  152. A. Evangelou, S. K. Jindal, T. J. Brown, and M. Letarte, “Down-regulation of transforming growth factor β receptors by androgen in ovarian cancer cells,” Cancer Research, vol. 60, no. 4, pp. 929–935, 2000. View at Google Scholar · View at Scopus
  153. E. Giovannucci, D. M. Harlan, M. C. Archer et al., “Diabetes and cancer: a consensus report,” CA: A Cancer Journal for Clinicians, vol. 60, no. 4, pp. 207–221, 2010. View at Publisher · View at Google Scholar · View at Scopus
  154. L. G. Hemkens, R. Bender, U. Grouven, and P. T. Sawicki, “Insulin glargine and cancer,” The Lancet, vol. 374, no. 9703, pp. 1743–1744, 2009. View at Publisher · View at Google Scholar · View at Scopus
  155. S. Jabbour, “Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both?” International Journal of Clinical Practice, vol. 62, no. 6, pp. 845–847, 2008. View at Publisher · View at Google Scholar · View at Scopus
  156. C. J. Currie, C. D. Poole, and E. A. M. Gale, “The influence of glucose-lowering therapies on cancer risk in type 2 diabetes,” Diabetologia, vol. 52, no. 9, pp. 1766–1777, 2009. View at Publisher · View at Google Scholar · View at Scopus
  157. J. M. Jonasson, R. Ljung, M. Talbäck, B. Haglund, S. Gudbjörnsdòttir, and G. Steineck, “Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden,” Diabetologia, vol. 52, no. 9, pp. 1745–1754, 2009. View at Publisher · View at Google Scholar · View at Scopus
  158. H. M. Colhoun, “Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group,” Diabetologia, vol. 52, no. 9, pp. 1755–1765, 2009. View at Publisher · View at Google Scholar · View at Scopus
  159. L. G. Hemkens, U. Grouven, R. Bender et al., “Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study,” Diabetologia, vol. 52, no. 9, pp. 1732–1744, 2009. View at Publisher · View at Google Scholar · View at Scopus
  160. S. J. Pocock and L. Smeeth, “Insulin glargine and malignancy: an unwarranted alarm,” The Lancet, vol. 374, no. 9689, pp. 511–513, 2009. View at Publisher · View at Google Scholar · View at Scopus
  161. M. Janghorbani, M. Dehghani, and M. Salehi-Marzijarani, “Systematic review and meta-analysis of insulin therapy and risk of cancer,” Hormones and Cancer, vol. 3, no. 4, pp. 137–146, 2012. View at Publisher · View at Google Scholar · View at Scopus
  162. R. Ljung, M. Talbäck, B. Haglund, J. M. Jonasson, S. Gudbjörnsdòttir, and G. Steineck, “Insulin glargine use and short-term incidence of breast cancer a four-year population-based observation,” Acta Oncologica, vol. 51, no. 3, pp. 400–402, 2012. View at Publisher · View at Google Scholar · View at Scopus
  163. S. Suissa, L. Azoulay, S. Dell'Aniello, M. Evans, J. Vora, and M. Pollak, “Long-term effects of insulin glargine on the risk of breast cancer,” Diabetologia, vol. 54, no. 9, pp. 2254–2262, 2011. View at Publisher · View at Google Scholar · View at Scopus
  164. M. K. Leow, “Basal insulin and cardiovascular and other outcomes,” The New England Journal of Medicine, vol. 367, no. 18, pp. 1763–1764, 2012. View at Google Scholar · View at Scopus
  165. D. M. Nathan, J. B. Buse, and M. B. Davidson, “Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American diabetes association and the European association for the study of diabetes,” Diabetes Care, vol. 32, no. 1, pp. 193–203, 2009. View at Publisher · View at Google Scholar
  166. R. Giannarelli, M. Aragona, A. Coppelli, and S. Del Prato, “Reducing insulin resistance with metformin: the evidence today,” Diabetes & Metabolism, vol. 29, no. 4, part 2, pp. 6–S28, 2003. View at Publisher · View at Google Scholar · View at Scopus
  167. R. J. Shaw, K. A. Lamia, D. Vasquez et al., “The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin,” Science, vol. 310, no. 5754, pp. 1642–1646, 2005. View at Publisher · View at Google Scholar · View at Scopus
  168. A. DeCensi, M. Puntoni, P. Goodwin et al., “Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis,” Cancer Prevention Research, vol. 3, no. 11, pp. 1451–1461, 2010. View at Publisher · View at Google Scholar · View at Scopus
  169. G. W. D. Landman, N. Kleefstra, K. J. J. van Hateren, K. H. Groenier, R. O. B. Gans, and H. J. G. Bilo, “Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16,” Diabetes Care, vol. 33, no. 2, pp. 322–326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  170. Z. B. Mei, Z. J. Zhang, C. Y. Liu et al., “Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis,” PLoS ONE, vol. 9, no. 3, Article ID e91818, 2014. View at Publisher · View at Google Scholar · View at Scopus
  171. H. Noto, A. Goto, T. Tsujimoto, and M. Noda, “Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis,” PLoS ONE, vol. 7, no. 3, Article ID e33411, 2012. View at Publisher · View at Google Scholar · View at Scopus
  172. M. Martin and R. Marais, “Metformin: a diabetes drug for cancer, ora cancer drug for diabetics?” Journal of Clinical Oncology, vol. 30, no. 21, pp. 2698–2700, 2012. View at Publisher · View at Google Scholar · View at Scopus
  173. R. Rattan, R. Ali Fehmi, and A. Munkarah, “Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis,” Journal of Oncology, vol. 2012, Article ID 928127, 12 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  174. E. J. Gallagher and D. Leroith, “Diabetes, cancer, and metformin: connections of metabolism and cell proliferation,” Annals of the New York Academy of Sciences, vol. 1243, no. 1, pp. 54–68, 2011. View at Publisher · View at Google Scholar · View at Scopus
  175. H. Lee, H. J. Park, C.-S. Park et al., “Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined,” PLoS ONE, vol. 9, no. 2, Article ID e87979, 2014. View at Publisher · View at Google Scholar
  176. D. G. Hardie, “Neither LKB1 nor AMPK are the direct targets of metformin,” Gastroenterology, vol. 131, no. 3, pp. 973–975, 2006. View at Publisher · View at Google Scholar · View at Scopus
  177. R. J. O. Dowling, M. Zakikhani, I. G. Fantus, M. Pollak, and N. Sonenberg, “Metformin inhibits mammalian target of rapamycin—dependent translation initiation in breast cancer cells,” Cancer Research, vol. 67, no. 22, pp. 10804–10812, 2007. View at Publisher · View at Google Scholar · View at Scopus
  178. M. Zakikhani, R. Dowling, I. G. Fantus, N. Sonenberg, and M. Pollak, “Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells,” Cancer Research, vol. 66, no. 21, pp. 10269–10273, 2006. View at Publisher · View at Google Scholar · View at Scopus
  179. I. N. Alimova, B. Liu, Z. Fan et al., “Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro,” Cell Cycle, vol. 8, no. 6, pp. 909–915, 2009. View at Publisher · View at Google Scholar · View at Scopus
  180. B. Liu, Z. Fan, S. M. Edgerton et al., “Metformin induces unique biological and molecular responses in triple negative breast cancer cells,” Cell Cycle, vol. 8, no. 13, pp. 2031–2040, 2009. View at Publisher · View at Google Scholar · View at Scopus
  181. M. Zakikhani, R. J. O. Dowling, N. Sonenberg, and M. N. Pollak, “The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase,” Cancer Prevention Research, vol. 1, no. 5, pp. 369–375, 2008. View at Publisher · View at Google Scholar · View at Scopus
  182. V. N. Anisimov, L. M. Berstein, P. A. Egormin et al., “Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice,” Experimental Gerontology, vol. 40, no. 8-9, pp. 685–693, 2005. View at Publisher · View at Google Scholar · View at Scopus
  183. M. B. Schneider, H. Matsuzaki, J. Haorah et al., “Prevention of pancreatic cancer induction in hamsters by metformin,” Gastroenterology, vol. 120, no. 5, pp. 1263–1270, 2001. View at Publisher · View at Google Scholar · View at Scopus
  184. C. Algire, M. Zakikhani, M.-J. Blouin, J. H. Shuai, and M. Pollak, “Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth,” Endocrine-Related Cancer, vol. 15, no. 3, pp. 833–839, 2008. View at Publisher · View at Google Scholar · View at Scopus
  185. J. M. M. Evans, L. A. Donnelly, A. M. Emslie-Smith, D. R. Alessi, and A. D. Morris, “Metformin and reduced risk of cancer in diabetic patients,” British Medical Journal, vol. 330, no. 7503, pp. 1304–1305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  186. S. Jiralerspong, S. L. Palla, S. H. Giordano et al., “Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer,” Journal of Clinical Oncology, vol. 27, no. 20, pp. 3297–3302, 2009. View at Publisher · View at Google Scholar · View at Scopus
  187. Z.-J. Zhang and S. Li, “The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis,” Diabetes, Obesity and Metabolism, vol. 16, no. 8, pp. 707–710, 2014. View at Publisher · View at Google Scholar · View at Scopus
  188. R. J. Stevens, R. Ali, C. R. Bankhead et al., “Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials,” Diabetologia, vol. 55, no. 10, pp. 2593–2603, 2012. View at Publisher · View at Google Scholar · View at Scopus
  189. N. F. Col, L. Ochs, V. Springmann, A. K. Aragaki, and R. T. Chlebowski, “Metformin and breast cancer risk: a meta-analysis and critical literature review,” Breast Cancer Research and Treatment, vol. 135, no. 3, pp. 639–646, 2012. View at Publisher · View at Google Scholar · View at Scopus
  190. H. Hauner, “The mode of action of thiazolidinediones,” Diabetes/Metabolism Research and Reviews, vol. 18, supplement 2, pp. S10–S15, 2002. View at Publisher · View at Google Scholar · View at Scopus
  191. D. Panigrahy, S. Huang, M. W. Kieran, and A. Kaipainen, “PPARγ as a therapeutic target for tumor angiogenesis and metastasis,” Cancer Biology and Therapy, vol. 4, no. 7, pp. 687–693, 2005. View at Publisher · View at Google Scholar · View at Scopus
  192. A. Rubenstrunk, R. Hanf, D. W. Hum, J.-C. Fruchart, and B. Staels, “Safety issues and prospects for future generations of PPAR modulators,” Biochimica et Biophysica Acta (BBA)—Molecular and Cell Biology of Lipids, vol. 1771, no. 8, pp. 1065–1081, 2007. View at Publisher · View at Google Scholar · View at Scopus
  193. K. Ohta, T. Endo, K. Haraguchi, J. M. Hershman, and T. Onaya, “Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells,” The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 5, pp. 2170–2177, 2001. View at Publisher · View at Google Scholar · View at Scopus
  194. C. Blanquicett, J. Roman, and C. M. Hart, “Thiazolidinediones as anti-cancer agents,” Cancer Therapy, vol. 6, pp. 25–34, 2008. View at Google Scholar
  195. J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435, 2002. View at Publisher · View at Google Scholar · View at Scopus
  196. D. Panigrahy, L. Q. Shen, M. W. Kieran, and A. Kaipainen, “Therapeutic potential of thiazolidinediones as anticancer agents,” Expert Opinion on Investigational Drugs, vol. 12, no. 12, pp. 1925–1937, 2003. View at Publisher · View at Google Scholar · View at Scopus
  197. D. Panigrahy, S. Singer, L. Q. Shen et al., “PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis,” The Journal of Clinical Investigation, vol. 110, no. 7, pp. 923–932, 2002. View at Publisher · View at Google Scholar · View at Scopus
  198. E. Saez, J. Rosenfeld, A. Livolsi et al., “PPARγ signaling exacerbates mammary gland tumor development,” Genes & Development, vol. 18, no. 5, pp. 528–540, 2004. View at Publisher · View at Google Scholar · View at Scopus
  199. K. Yang, K.-H. Fan, S. A. Lamprecht et al., “Peroxisome proliferator-activated receptor γ agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice,” International Journal of Cancer, vol. 116, no. 4, pp. 495–499, 2005. View at Publisher · View at Google Scholar · View at Scopus
  200. E. Saez, P. Tontonoz, M. C. Nelson et al., “Activators of the nuclear receptor PPARγ enhance colon polyp formation,” Nature Medicine, vol. 4, no. 9, pp. 1058–1061, 1998. View at Publisher · View at Google Scholar · View at Scopus
  201. C. Koro, S. Barrett, and N. Qizilbash, “Cancer risks in thiazolidinedione users compared to other anti-diabetic agents,” Pharmacoepidemiology and Drug Safety, vol. 16, no. 5, pp. 485–492, 2007. View at Publisher · View at Google Scholar · View at Scopus
  202. R. Govindarajan, L. Ratnasinghe, D. L. Simmons et al., “Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1476–1481, 2007. View at Publisher · View at Google Scholar · View at Scopus
  203. M. E. Ramos-Nino, C. D. MacLean, and B. Littenberg, “Association between cancer prevalence and use of thiazolidinediones: results from the vermont diabetes information system,” BMC Medicine, vol. 5, article 17, 2007. View at Publisher · View at Google Scholar · View at Scopus
  204. X. He, F. J. Esteva, J. Ensor, G. N. Hortobagyi, M.-H. Lee, and S.-C. J. Yeung, “Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer,” Annals of Oncology, vol. 23, no. 7, Article ID mdr534, pp. 1771–1780, 2012. View at Publisher · View at Google Scholar · View at Scopus
  205. C.-H. Tseng, “Pioglitazone does not affect the risk of ovarian cancer: analysis of a nationwide reimbursement database in Taiwan,” Gynecologic Oncology, vol. 131, no. 1, pp. 135–139, 2013. View at Publisher · View at Google Scholar · View at Scopus
  206. M. Monami, C. Lamanna, N. Marchionni, and E. Mannucci, “Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials,” Diabetes Care, vol. 31, no. 7, pp. 1455–1460, 2008. View at Publisher · View at Google Scholar · View at Scopus
  207. M. Monami, I. Dicembrini, and E. Mannucci, “Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials,” Acta Diabetologica, vol. 51, no. 1, pp. 91–101, 2014. View at Publisher · View at Google Scholar · View at Scopus